Management of advanced non-small-cell lung cancer in patients with a performance status of 2

Clinical Lung Cancer

Volumn 5, Issue 4, 2004, Pages 209-213

  Lilenbaum, Rogerio ^a  

^a Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

Combination therapy; Gemcitabine; Platinum compounds; Subset analysis; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINDESINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEALTH STATUS; HUMAN; LUNG NON SMALL CELL CANCER; MORBIDITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SYMPTOMATOLOGY; TASK PERFORMANCE; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 1542360611     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.001     Document Type: Review

References (20)

1. Lilenbaum R, Herndon J, Est M, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21:1a (Abstract #2).
2. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:199-205.
3. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25-32.
4. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4:14-22.
5. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-1626.
6. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-1230.
7. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-367.
8. Le Chevalier T, Brisgand D, Soria JC, et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6:(suppl 1):8-11.
9. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-3194.
10. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001; 12:1671-1675.
11. Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 2003; 40:191-199.
12. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001; 12:1221-1230.
13. Hickish TF, Smith IE, O'Brien ME, et al. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 1998; 78:28-33.
14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
15. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92:2639-2647.
16. Langer C, Stephenson P, Schiller J, et al. ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. Lung Cancer 2003; 41(suppl 2):S18.
17. Lilenbaum R. Management of advanced non-small-cell lung cancer in elderly populations. Clin Lung Cancer 2003; 5:169-173.
18. Group N-SCLCC-O. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.
19. Taylor AE, Olver IN, Sivanthan T, et al. Observer error in grading performance status in cancer patients. Support Care Cancer 1999; 7:332-335.
20. Ando M, Ando Y, Hasegawa Y. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001; 85:1634-1639.